IK-930
- Generic Name
- IK-930
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
IK-930 is an oral, paralog-selective TEAD inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ikena Oncology
- Target Recruit Count
- 67
- Registration Number
- NCT05228015
- Locations
- 🇦🇺
Peninsula South Eastern Haematology and Oncology Group (PASO Medical), Frankston, Victoria, Australia
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath